Georgia's Online Cancer Information Center

Find A Treatment Site

Aflac Cancer and Blood Disorders Center of Children’s at Egleston

The Aflac Cancer Center is pediatric cancer center that provides advanced medical treatment, through clinical trials, and offers family-centered care and a child-friendly environment. Aflac Cancer Center physicians are involved in national clinical trials and collaborative studies of the Children’s Oncology Group (COG), the National Cancer Institute, the National Institutes of Health and the Pediatric Blood and Marrow Transplant Consortium. The Aflac Cancer Center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers. Children’s Healthcare of Atlanta is accredited by the American College of Radiology (ACR). Located in Atlanta, Georgia, the Aflac Cancer Center has three locations: Children’s at Egleston, Children's at Hughes Spalding and Children’s at Scottish Rite. Each location features the following services: full range of pediatric infusional and apheresis services; onsite, innovative diagnostics, cell processing laboratory and oncology pharmacy; a 20-plus-member family support team—including child life specialists, social workers, chaplains, teachers, psychologists and financial coordinators—that attends to the patient’s and family’s emotional, physical and financial well-being, as well as help the family identify and use all available resources during this difficult time.

Treatment Sites in Georgia

Clinical Trials in Georgia

A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Cancer Type: Leukemia

A Feasibility Trial of MLN4924 (Pevonedistat,TAK924) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome
Cancer Type: Myelodysplastic Syndromes (MDS)

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Cancer Type: Multiple Primaries
Study Coordinator: Sindy Midoro


A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma
Cancer Type: Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Lymphoma, Neuroblastoma

A Pediatric Brain Tumor Consortium Phase I / II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma
Cancer Type: Unspecified

A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Cancer Type: Unspecified

A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
Cancer Type: Unknown Primary

A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Cancer Type: Lymphoma

A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Cancer Type: Brain Cancer , Eye Cancer, Non-Hodgkin Lymphoma, Unknown Primary

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Cancer Type: Bone and Soft Tissue (including Sarcoma), Chondrosarcoma

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma

A Phase 1 Study Using Nab-Paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Cancer Type: Unspecified

A Phase 1 Trial using Everolimus in Combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T cell Lymphoblastic Leukemia / Lymphoma
Cancer Type: Lymphoma

A Phase 2 Randomized Study of Irinotecan / Temozolomide / Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Cancer Type: Neuroblastoma

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Cancer Type: Acute Lymphoblastic Leukemia

A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Cancer Type: Myelodysplastic Syndromes (MDS)

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
Cancer Type: Unspecified

A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed / Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Cancer Type: Ewing Sarcoma

A Phase 3 Randomized Study of Selumetinib versus Carboplatin / Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Cancer Type: Unspecified

A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Cancer Type: Lymphoma

A Phase I / II Study of Nivolumab in Combination With 5-azacytidine in Pediatric Patients With Relapsed / Refractory Acute Myeloid Leukemia (BMS Reference CA209-9JY)
Cancer Type: Unspecified

A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab + / - Lenalidomide
Cancer Type: Neuroblastoma, Unknown Primary

A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed / Refractory Neuroblastoma
Cancer Type: Neuroblastoma

A Phase II Study Of Pegylated Interferon ALFA-2b (PEG-INTRON™) in Children With Recurrent or Refractory and Radiographically or Clinically Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Cancer Type: Brain Cancer

A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors
Cancer Type: Unknown Primary

A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Cancer Type: Lymphoma

A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine + / - Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)
Cancer Type: Unspecified

A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Cancer Type: Lymphoma

A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Pegylated L-Asparaginase
Cancer Type: Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma

A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patients (Age > / = 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Cancer Type: Lymphoma

A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-transplant Lymphoproliferative Disease (PTLD)
Cancer Type: Lymphoma, Unknown Primary

A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
Cancer Type: Acute Lymphoblastic Leukemia, Leukemia, Lymphoma

A Randomised Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours
Cancer Type: Germ Cell Tumor, Ovarian Cancer

A Randomized Phase 2 Trial of Axitinib / Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE / Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Cancer Type: Kidney Cancer, Unknown Primary

A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
Cancer Type: Non-Hodgkin Lymphoma

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Cancer Type: Non-Hodgkin Lymphoma

A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children with Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Cancer Type: Brain Cancer

Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors, A Phase I Study
Cancer Type: Brain Cancer

An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Cancer Type: Adrenal Cancer, Neuroblastoma

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
Cancer Type: Unspecified

Antiviral Cellular Therapy for Enhancing T-Cell Reconstitution before or after Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Cancer Type: Unspecified

Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
Cancer Type: Unspecified

Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Cancer Type: Bone and Soft Tissue (including Sarcoma)

Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed / Refractory AML
Cancer Type: Acute Myelogenous Leukemia, Leukemia

Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Cancer Type: Brain Cancer

Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Cancer Type: Hodgkin Lymphoma

Improving Health-Promoting Behaviors in Adolescent Cancer Survivors Using AWAKE: A Feasibility Trial
Cancer Type: Unspecified

Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Cancer Type: Acute Lymphoblastic Leukemia

Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Cancer Type: Unspecified

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Cancer Type: Unspecified

LEAHRN (Late Effects after High-Risk Neuroblastoma) Study
Cancer Type: Neuroblastoma

Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias
Cancer Type: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)

Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Cancer Type: Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)

N2004-05: Neuroblastoma Biology Study
Cancer Type: Neuroblastoma

N2015-01: Neuroblastoma Precision Trial
Cancer Type: Unspecified

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Cancer Type: Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1 / 2 / 3 / 4 Alterations
Cancer Type: Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
Cancer Type: Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
Cancer Type: Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
Cancer Type: Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
Cancer Type: Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Unknown Primary

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI / SNF Complex
Cancer Type: Ewing Sarcoma

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations
Cancer Type: Bone and Soft Tissue (including Sarcoma)

Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Cancer Type: Unknown Primary

Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK / ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma
Cancer Type: Neuroblastoma

PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE (REGISTERED)) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
Cancer Type: Ewing Sarcoma, Neuroblastoma

Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT (SJATRT)
Cancer Type: Unspecified

Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG
Cancer Type: Unspecified

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Cancer Type: Ewing Sarcoma, Kidney Cancer, Unknown Primary

Phase I Study of MEK 162 for Children with Progressive or Recurrent Cancer and a Phase II Study for Children with Low-Grade Gliomas and Other Ras / Raf / MAP Pathway Activated Tumors
Cancer Type: Brain Cancer , Unknown Primary

Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent / Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Cancer Type: Brain Cancer

Phase II Study of Nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent / Refractory Sarcoma in Teenagers and Young Adults
Cancer Type: Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma

Pilot Study of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk Medulloblastoma
Cancer Type: Brain Cancer

Pilot Study of Neuropsychological and Behavioral Assessment in Children With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)
Cancer Type: Brain Cancer
Study Coordinator: Sindy Midoro


Research Study of Clinical, Genetic, and Biological Factors as Prognostic Values in Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Cancer Type: Neuroblastoma
Study Coordinator: Sindy Midoro


Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
Cancer Type: Unspecified

Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed / Refractory (R / R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
Cancer Type: Lymphoma

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Cancer Type: Unspecified

Study of Key Late-Occurring Complications in Childhood Cancer Survivors
Cancer Type: Multiple Primaries
Study Coordinator: Sindy Midoro


Study of Long-Term Follow-Up in Patients Who Have Participated in Children's Oncology Group Studies
Cancer Type: Multiple Primaries
Study Coordinator: Sindy Midoro


Study of Renal Tumors in Pediatric Patients
Cancer Type: Kidney Cancer
Study Coordinator: Sindy Midoro


The "Head Start 4" Protocol Newly Diagnosed Children (Less than 10 Years Old) with Medulloblastoma and Other Central Nervous System Primitive Neuro-ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single Cycle (Low Risk Patients) or Randomization (High Risk Patients) to Either Single-Cycle (Low Risk Patients) or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenit
Cancer Type: Brain Cancer
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.